Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial

Lancet

Volumn 356, Issue 9234, 2000, Pages 961-967

  Levin, Michael ^a   Quint, Peter A ^b   Goldstein, Brahm ^c   Barton, Phil ^d   Bradley, John S ^e   Shemie, S D ^f   Yeh, Timothy ^g   Kim, Sun Sook ^h   Cafaro, Daniel P ^h   Scannon, Patrick J ^h   Giroir, Brett P ⁱ  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LEGACY EMANUEL HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Children's Hospital at Saint Francis   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g CHILDREN S HOSPITAL OAKLAND   (United States)

^h XOMA Corporation   (United States)

ⁱ CHILDREN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; ENDOTOXIN; PLACEBO;

ADOLESCENT; ADULT; AMPUTATION; ARTICLE; BLOOD TRANSFUSION; BRAIN DEATH; CHILD; CLINICAL TRIAL; COMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FULMINATING PURPURA; HUMAN; INFANT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NEWBORN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOCK; TREATMENT OUTCOME;

EID: 0034675328     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02712-4     Document Type: Article

References (30)

1. Epidemiology of meningococcal disease in Europe and the USA
2. Pathophysiology and management of meningococcal disease septicaemia
3. Treatment of meningococcal disease in childhood
4. Pathogenesis of meningococcal infections
5. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock
6. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience
7. Update on meningococcal disease with emphasis on pathogenesis and clinical management
8. Prospects for use of rBPI fragments in the treatment of gram-negative bacterial infections
9. Role of the bactericidal/permeability-increasing protein in host defence
10. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils
11. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria
12. 23) is a universal lipopolysaccharide-binding ligand
13. 23
14. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein
15. Pathogenesis of hemorrhage-induced bacteria/endotoxin translocation in rats: Effects of recombinant bactericidal/permeability-increasing protein
16. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in endotoxemia and gram-negative sepsis
17. An N-terminal fragment of bactericidal/permeability-increasing protein protects against hemodynamic and metabolic derangements in rat gram-negative sepsis
18. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans using recombinant bactericidal/permeability-increasing protein
19. 23)
20. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
21. Validation of the Glasgow Meningococcal Septicemia Prognostic Score: A year retrospective survey
22. Assessing the outcome of pediatric intensive care
23. Relationship of illness severity and length of stay to functional outcomes in the pediatric intensive care unit: A multi-institutional study
24. PRISM III: An updated Pediatric Risk of Mortality score
25. Adjunctive therapy in sepsis: A critical analysis of the clinical trial program
26. Factors for poor prognosis in fulminating meningococcemia: Conclusions from observations of 67 childhood cases
27. Factors affecting outcome in meningococcal infections
28. Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura
29. Clinical manifestations and course of meningococcal disease in 562 patients
30. Pathophysiology of meningococcal sepsis in children